Literature DB >> 18995899

Rituximab for the treatment of CD20-positive peripheral T-cell lymphoma, unspecified.

Yuji Hirata, Taiji Yokote, Kichinosuke Kobayashi, Shoko Nakayama, Takuji Miyoshi, Toshikazu Akioka, Satoshi Hara, Motomu Tsuji, Takayuki Takubo, Toshiaki Hanafusa.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18995899     DOI： 10.1016/j.leukres.2008.09.034

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


× No keyword cloud information.
  3 in total

1.  Peripheral T-cell lymphoma with aberrant expression of CD30, CD15, and CD20.

Authors:  Joo Y Song; Ted Strom; Mark Raffeld; Stefania Pittaluga; Elaine S Jaffe
Journal:  J Clin Oncol       Date:  2011-10-11       Impact factor: 44.544

2.  CD20dim-positive T-cell large granular lymphocytic leukemia in a patient with concurrent hairy cell leukemia and plasma cell myeloma.

Authors:  Xiangdong Xu; Elizabeth H Broome; Hooman H Rashidi; Sarah T South; Marie L Dell'aquila; Huan-You Wang
Journal:  Int J Clin Exp Pathol       Date:  2010-09-12

Review 3.  CD20-positive primary gastric T-cell lymphoma poorly responding to initial treatment with rituximab plus CHOP, and a literature review.

Authors:  Yasutaka Kakinoki; Junichi Hashiguchi; Takashi Ishio; Koji Chiba; Daisuke Niino; Koichi Ohshima
Journal:  Int J Hematol       Date:  2015-08-07       Impact factor: 2.490
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.